Faropenem is an oral penem antibiotic belonging to the beta-lactam class. It is a broad-spectrum antibiotic with bactericidal activity against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria. It is particularly valuable in the Indian context for treating community-acquired infections due to its stability against many beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) produced by common pathogens like E. coli and Klebsiella spp.
Adult: 200 mg orally every 8 hours (for mild-moderate infections) or every 12 hours (for less severe infections). Typical duration: 7-14 days depending on infection.
Note: Administer on an empty stomach, at least 1 hour before or 2 hours after meals, to maximize bioavailability. The tablet should be swallowed whole with a glass of water. Do not crush or chew.
Faropenem is a bactericidal beta-lactam antibiotic. It binds to and inhibits penicillin-binding proteins (PBPs), particularly PBP-2, located on the inner membrane of the bacterial cell wall. This inhibition disrupts the final transpeptidation step of peptidoglycan synthesis, a critical component of the bacterial cell wall. The resulting defective cell wall structure leads to osmotic instability, cell lysis, and death.
Pregnancy: Category B: Animal reproduction studies have not shown a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed, weighing benefits against potential risks.
Driving: May cause dizziness. Patients should be cautioned about operating machinery or driving until they are certain faropenem does not affect them adversely.
| Probenecid | Markedly decreases renal tubular secretion of faropenem, leading to increased and prolonged plasma concentrations. Contraindicated. | Major |
| Valproic Acid | Faropenem may significantly reduce serum valproic acid levels, potentially leading to loss of seizure control. | Major |
| Methotrexate | Potential for decreased renal clearance of methotrexate, increasing risk of toxicity. Monitor closely. | Moderate |
| Other antibiotics (e.g., Aminoglycosides) | Potential synergistic effect against some organisms, but no significant PK interaction. | Minor |